NCT03311607View on ClinicalTrials.gov

Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh

PHASE4CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

April 8, 2014

Primary Completion Date

October 14, 2015

Study Completion Date

October 14, 2015

Conditions
Post-kala-azar Dermal Leishmaniasis
Interventions
DRUG

AmBisome

A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule

All Listed Sponsors
lead

Medecins Sans Frontieres, Netherlands

OTHER

NCT03311607 - Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh | Biotech Hunter | Biotech Hunter